[1] Villet S,Pichoud C,Billioud G,et al.Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.J Hepatol.2008,48:747-755.
[2] EASL 2017 Clinical Practice Guidelines onthe management of hepatitis B virus infection.J Hepatol,2017,67:370-398.
[3] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版)实用肝脏病杂志,2016,19:389-400.
[4] Walsh AW,Langley DR,Colonno RJ,et al.Mechanistic characterization and molecularmodeling of hepatitis b virus polymerase resistance to entecavir.PLoS One,2010,5:e9195.
[5] Amini-Bavil-Olyaee S,Herbers U,Sheldon J,et al.The rta194t polymerase mutationimpacts viral replication and susceptibility to tenofovir inhepatitis b e antigen-positive and hepatitis b e antigen-negative hepatitis b virus strains.Hepatology,2009,49:1158-1165.
[6] Zhao L,Li X,Cheng Y,et al.Hepatitis b virus rta181t/sw172 non-stop mutation may increase resistance fold to adefovirand entecavir-resistant mutants compared to rta181T/sw172* mutation.Antiviral Res,2018,154:26-34. |
